CHMP recommends the EU weight management indication for Mounjaro

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion on Nov. 9, 2023, recommending that Mounjaro's approved uses in the European Union be expanded to include chronic weight management ^[1]. The European Commission then issued a formal decision adopting that recommendation on Dec. 11, 2023 ^[1]. Mounjaro is the brand name for tirzepatide, a once-weekly injectable medicine.

The recommendation, filed under application II/0007, covers weight loss and weight maintenance as an add-on to a reduced-calorie diet and more physical activity ^[1]. Under the new indication, adults could qualify if they have a body mass index (BMI) of 30 or higher, which is classified as obesity, or a BMI between 27 and just under 30 combined with at least one weight-related health condition ^[1].

The evidence behind the decision came from six late-stage clinical trials. The main study was SURMOUNT-1, a phase 3 trial that tested tirzepatide against a placebo in adults without type 2 diabetes who had obesity or were overweight with weight-related health problems ^[1]. Five additional studies, called SURPASS-1 through SURPASS-5, supported the application; those trials looked at tirzepatide in people who had type 2 diabetes and a BMI of 27 or higher ^[1]. Regulators used all six studies together to evaluate both how well the drug worked and its safety profile.

As part of the change, four sections of the drug's official prescribing document, called the Summary of Product Characteristics, were updated: sections 4.1 (indications), 4.8 (side effects), 5.1 (how the drug works) and 5.2 (how the body processes it) ^[1]. The patient package leaflet was updated to match. The manufacturer also submitted an updated risk management plan, version 2.1, which lays out how safety will continue to be monitored, and made some additional minor edits to the product information at the same time ^[1].

Why it matters for patients

This was a regulatory action in the European Union, not the United States, so it does not by itself change what is available or approved for U.S. patients. The U.S. Food and Drug Administration makes its own separate decisions about tirzepatide, which is sold in the U.S. as Mounjaro for type 2 diabetes and as Zepbound for weight management.

Still, the underlying trial data are the same body of evidence used by regulators worldwide, including SURMOUNT-1 and the SURPASS series ^[1]. When a major regulator like the EMA reviews and accepts this evidence for a weight-management use, it can be a signal of how consistently the drug performed across different studies and patient groups, including people with and without type 2 diabetes ^[1].

For people already taking Mounjaro or Zepbound in the U.S., or considering it, this development does not change the U.S. label, dosing, or availability. It reflects how a different country's regulator interpreted the same or similar clinical trial results.

What happens next

The CHMP opinion was issued Nov. 9, 2023, and the European Commission adopted the decision on Dec. 11, 2023, which formally updated Mounjaro's authorized uses in the EU ^[1]. The source document does not describe any related U.S. regulatory action tied to this specific EU filing, so what, if anything, this means for U.S. approvals is not yet known from these records.